Home4C Medical Technologies IncAltaValve, 4C Medical's Novel Transcatheter Mitral Regurgitation Device Highlighted at TCT 2019

AltaValve, 4C Medical’s Novel Transcatheter Mitral Regurgitation Device Highlighted at TCT 2019

September 30, 2019

AltaValve, for mitral regurgitation, was featured at Transcatheter Cardiovascular Therapeutics (TCT) 2019, on Sept 25-29 in San Francisco, CA.

AltaValve is a Transcatheter Mitral Valve Replacement (TMVR) device designed to broaden the treatable patient population: the device’s supra-annular fit and atrial-only fixation bypass the concerns of anchoring and fixation difficulties present in current TMVR technologies. Moreover, AltaValve leaves the left ventricle geometry intact and minimizes the risks of left ventricular outflow tract (LVOT) obstruction and damage to the left ventricle.

“AltaValve is the only device that truly differentiated itself in a crowded TMVR market. Delivered transseptally, AltaValve can be implanted using a very simple procedure, suitable for the vast majority of patients suffering of MR. Due to its unique supra-annular design, more patients will qualify for treatment with AltaValve. More importantly, AltaValve has the potential to be the only TMVR that could be implanted in patients with previously failed mitral edge-to-edge repair,” said Philippe Généreux, MD, Co-Director of the Structural Heart Program at the Gagnon Cardiovascular Institute of Morristown Medical Center (Morristown, NJ). “AltaValve is truly an innovative, scalable technology that answers a real unmet need. It has the potential to become the TAVR of the mitral space.”

Dr. Généreux highlighted AltaValve in the presentation titled “AltaValve – Device Description, Results, and Ongoing Studies” which was part of the TMVR Overview and Principle Devices session.

“It’s no easy task to redefine solutions for structural heart disease, but we’re doing it. We’ve continued our commitment to improve quality of life for patients with mitral regurgitation (MR),” said Robert Thatcher, CEO of 4C Medical Technologies, Inc.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy